On this page
What it is
5-Amino-1MQ is a small-molecule NNMT inhibitor, not a peptide — despite being sold on peptide sites alongside GLP-1 and other research compounds, it's a simple methylquinolinium chemical, not a chain of amino acids. It's worth flagging that difference because the biology and the (absent) safety data are quite different from studied peptides.
It was designed by academic researchers (notably a group at UTMB/Vanderbilt) as a tool to test whether blocking the enzyme NNMT could treat obesity and metabolic disease. It is sold strictly 'for laboratory research use only' and is not an approved drug, supplement, or medicine.
Almost everything known about it comes from cell cultures and mice. There is no established human dose, no FDA review, and no published human clinical trial confirming it does anything in people.
What people research it for
Reduced body weight and fat mass
Animal studiesObese mice given the compound lost body weight and white-fat mass without eating less, in the Neelakantan 2018 study.
Higher cellular NAD+ / SAM
Preclinical / theorizedIn cultured fat cells, blocking NNMT raised NAD+ and SAM and reduced lipogenesis (new fat formation).
Smaller fat cells, lower cholesterol
Animal studiesTreated mice showed reduced adipocyte size and lower plasma cholesterol; a later study also showed less liver fat.
Improved metabolic/energy markers
Preclinical / theorizedProposed 'increased energy expenditure' and better fat oxidation are extrapolated from rodent and cell data, not shown in people.
How it works
NNMT (nicotinamide N-methyltransferase) is an enzyme that's overactive in the fat tissue of obese, diabetic animals. It burns through two important cellular resources — nicotinamide (a building block of NAD+, the cell's energy-currency molecule) and SAM (a methyl donor). 5-Amino-1MQ slips into fat cells and blocks NNMT, which in lab studies lets NAD+ and SAM levels rise again.
In theory, more available NAD+ means fat cells can burn fuel more efficiently and build less new fat. In mouse and cell studies this translated to smaller fat cells and reduced fat storage without the animals eating less. Whether the same chain of events happens meaningfully in humans is unproven.
What the research actually shows
The foundational work is Kraus et al. (Nature, 2014), showing that knocking down NNMT in fat and liver protected mice from diet-induced obesity by raising cellular energy expenditure. This established NNMT as a metabolic target but used genetic silencing, not a drug.
The key drug study is Neelakantan et al. (Biochemical Pharmacology, 2018), which gave 5-Amino-1MQ to high-fat-diet obese mice (20 mg/kg subcutaneously, three times daily for 11 days). Treated mice lost body weight and fat mass, had smaller fat cells and lower cholesterol, with no change in food intake and no reported adverse effects in that short study. A 2022 Scientific Reports paper extended this with newer NNMT inhibitors and showed reduced liver fat.
Crucially, human data is essentially absent — there are no published, peer-reviewed human clinical trials of 5-Amino-1MQ demonstrating weight loss or safety. Everything above is mouse and cell-culture evidence.
Handling & storage
Storage at a glance
Vendor consensus- Light
- Keep tablets in the original sealed container, dry and protected from light.
- Room temperature
- Tablet sellers conflict: one says room temperature is acceptable, while research-material sellers specify -20°C. Use the actual product label rather than peptide-vial rules.
Basis: Vendor consensus. Sources: Pure US Peptide 5-amino-1MQ research-solid handling, Middle Way Nutrition capsule storage statement
5-amino-1MQ is a small molecule, not a peptide. Tablets or capsules should stay sealed, dry, and protected from light, and the exact product label should control storage. Tablet sellers allow room temperature while some neat research-solid sellers specify -20°C.
Do not refrigerate every product automatically and do not apply vial reconstitution instructions. Purity, dose, and formulation are not standardized across research products, so treat the actual presentation and label as decisive.
Safety & cautions
There is little to no human safety data. The short mouse studies reported no obvious adverse effects, but that says almost nothing about long-term safety, correct human dosing, drug interactions, or effects in people with medical conditions. Long-term NNMT inhibition could plausibly have off-target effects that rodent studies haven't captured.
5-Amino-1MQ is not FDA-approved and not a legal dietary supplement. It is sold for laboratory research use only. This guide is educational and is not medical advice or a dosing recommendation — anyone considering it should recognize the evidence is preclinical and speak with a qualified clinician.
Watch 5-Amino-1MQ prices
We'll email you when prices drop, a discount code changes, or new lab results come in for 5-Amino-1MQ. No spam — only real changes.
Frequently asked questions
Is 5-Amino-1MQ FDA approved?
No. It is not an approved drug or a legal dietary supplement. It's sold strictly 'for research use only' and has not been reviewed by the FDA for safety or effectiveness.
Is there human evidence it works?
Essentially none. There are no published human clinical trials showing it causes weight loss or is safe in people. All the encouraging results come from mice and cultured cells.
Is it a peptide?
No. It's a small molecule (an NNMT enzyme inhibitor). It's just commonly sold alongside peptides on the same research-chemical sites.
How is it thought to cause fat loss?
By blocking the NNMT enzyme in fat cells, which in lab studies raises NAD+ and reduces new fat formation. This mechanism is demonstrated in animals, not confirmed in humans.
How does it compare to GLP-1 drugs like semaglutide?
Very differently. GLP-1 medications are FDA-approved with large human trials; 5-Amino-1MQ is a preclinical research compound with no human trial evidence. They are not comparable in terms of proof.
Sources
- Neelakantan et al., 2018 — NNMT inhibitors reverse diet-induced obesity in mice (Biochem Pharmacol, PMID 29155147)
- Kraus et al., 2014 — NNMT knockdown protects against diet-induced obesity (Nature)
- Novel tricyclic NNMT inhibitors for metabolic disorders, 2022 (Scientific Reports)
- NNMT: a novel therapeutic target for metabolic syndrome — review, 2024 (Frontiers in Pharmacology / PMC)
Last reviewed July 7, 2026. This guide is educational and research-focused, not medical advice. 5-Amino-1MQ products referenced on PeptidePub are sold by third parties as materials for laboratory research use only, not for human or animal consumption.
GO DEEPER
This guide covers one compound. We wrote the book on all 45.
The Peptide Handbook takes everything we know from testing vendors for a living and turns it into five readable books: what each compound actually does, what the evidence really says, and the honest call when the answer is "skip this one." Plus the dosing tables, calendars, and trackers that make it usable.
From the community
Ask a questionNo 5-Amino-1MQ discussions yet — ask the first question and our team will answer.